Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial.
Sands BE, Panaccione R, D'Haens G, Schreiber S, Jairath V, DuVall A, Kierkus J, Walczak M, Naik S, Gilder K, Lindstrom B, Ogilvie K, Sandborn WJ, Vermeire S, Rubin DT, Peyrin-Biroulet L, Danese S.
Sands BE, et al. Among authors: gilder k.
Lancet Gastroenterol Hepatol. 2025 Jan 7:S2468-1253(24)00386-8. doi: 10.1016/S2468-1253(24)00386-8. Online ahead of print.
Lancet Gastroenterol Hepatol. 2025.
PMID: 39793589